Details of Disease

General Information of Disease (ID: DISEZJS7)

• Disease Name: Synovial sarcoma
• Synonyms: sarcoma, synovial; SS; sarcoma, synovial, malignant; Synovialosarcoma; synovial sarcoma; synovial sarcoma (disease)
• Disease Class: 2B5A: Synovial sarcoma
• Definition: Synovial sarcoma is an aggressive soft tissue sarcoma, occurring most commonly in adolescents and young adults (15 to 40 years), usually localized near the large joints of the extremities but also in the head and neck, mediastinum and viscera (lung, kidney etc), clinically presenting as a deep seated swelling or a painful mass often with an initial indolent course and is characterized by its local invasiveness and a propensity to metastasize. The origin of synovial sarcoma is likely from multipotent mesenchymal cells and not synovium (contrary to its name).|Synovial sarcomas are not necessarily of synovial origin.
• Disease Hierarchy:
  DISSN8XB: Soft tissue sarcoma
  DISEZJS7: Synovial sarcoma
• ICD Code:
  ICD-11: ICD-11: 2B5A
  ICD-9: ICD-9: 171
  Expand ICD-11: 'XH9B22
  Expand ICD-9: 171
• Disease Identifiers:
  MONDO ID: MONDO_0010434
  MESH ID: D013584
  UMLS CUI: C0039101
  OMIM ID: 300813
  MedGen ID: 21050
  HPO ID: HP:0012570
  Orphanet ID: 3273
  SNOMED CT ID: 302851001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Tazemetostat	DMWP1BH	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AL3818	DM3WP0N	Phase 3	NA	[1]
ADP-A2M4	DMRYH3M	Phase 2	NA	[2]
GSK3377794	DMQ4RWW	Phase 2	NA	[1]
Anti-NY-ESO-1 CAR-T cells	DM26VCZ	Phase 1/2	CAR T Cell Therapy	[3]
NY-ESO-TCR	DMS0L6J	Phase 1/2	NA	[4]
OTSA-101-DTPA-90Y	DMWIEC1	Phase 1	Antibody	[5]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 11 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BRD9	TTR7L5Y	Strong	Biomarker	[6]
CD38	TTPURFN	Strong	Biomarker	[7]
CSK	TTX6F0Q	Strong	Altered Expression	[8]
CTSS	TTUMQVO	Strong	Altered Expression	[9]
FZD10	TTP1S2F	Strong	Biomarker	[10]
HBA2	TTQO71U	Strong	Genetic Variation	[11]
MAGEA1	TT63M7Q	Strong	Biomarker	[12]
MAGEA4	TT9EQUY	Strong	Biomarker	[12]
OAT	TTTSCQ2	Strong	Genetic Variation	[13]
PRAME	TTPH7T0	Strong	Altered Expression	[14]
SHCBP1	TTZ9WGL	Strong	Biomarker	[15]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC3A1	DTBCKVM	Strong	Biomarker	[16]

This Disease Is Related to 50 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CCNB3	OT5V72D3	Limited	Biomarker	[17]
SMARCB1	OT2LP7LJ	Limited	Altered Expression	[18]
SSX4	OT0E4H2D	Disputed	Genetic Variation	[19]
ANKRD36B	OT3MW415	moderate	Biomarker	[20]
CRABP1	OTISDG5X	moderate	Altered Expression	[21]
EWSR1	OT7SRHV3	moderate	Genetic Variation	[22]
AQP8	OT99JKME	Strong	Biomarker	[23]
ATF2	OTNIZPEA	Strong	Biomarker	[24]
BANF1	OTP7Z38L	Strong	Biomarker	[25]
BCOR	OTG013AX	Strong	Biomarker	[26]
BIK	OTTH1T3D	Strong	Posttranslational Modification	[27]
CD99	OTPUZ5DE	Strong	Biomarker	[28]
DYM	OTQ670WI	Strong	Biomarker	[29]
ELF3	OTUTLEQO	Strong	Altered Expression	[30]
FRMPD2	OT8OM5MA	Strong	Altered Expression	[31]
FXYD5	OT81DIOD	Strong	Altered Expression	[32]
GAB1	OTQKE6V4	Strong	Posttranslational Modification	[33]
GDF6	OTERXWJU	Strong	Biomarker	[34]
GINS1	OTVQZMMQ	Strong	Biomarker	[35]
HBG1	OTVL4NSU	Strong	Biomarker	[36]
HBG2	OT4J48JJ	Strong	Genetic Variation	[37]
HEATR3	OTB52FZ4	Strong	Genetic Variation	[38]
INHA	OT7HWCO3	Strong	Genetic Variation	[39]
KCNH4	OTHJ8WTU	Strong	Biomarker	[40]
KCNH8	OT3I5FLB	Strong	Biomarker	[40]
KDM2B	OTDMCVW7	Strong	Biomarker	[41]
LBH	OT87AT1X	Strong	Biomarker	[42]
MED1	OTOO24C4	Strong	Altered Expression	[43]
NUPR1	OT4FU8C0	Strong	Altered Expression	[44]
PAX3	OTN5PJZV	Strong	Genetic Variation	[22]
PAX7	OTDMQRPO	Strong	Altered Expression	[45]
PDZD4	OTEBJTOU	Strong	Altered Expression	[31]
PIAS4	OTB7SVMZ	Strong	Altered Expression	[46]
PMCH	OT3D9SA4	Strong	Altered Expression	[47]
PPRC1	OT6GB3WR	Strong	Altered Expression	[48]
PRM3	OT6574BF	Strong	Biomarker	[49]
PUF60	OTG90DYF	Strong	Biomarker	[50]
RBBP8	OTRHJ3GI	Strong	Altered Expression	[44]
REPS2	OTSE3TRP	Strong	Genetic Variation	[51]
RPL34	OT0U9VMQ	Strong	Genetic Variation	[52]
SALL2	OTQWI68Q	Strong	Biomarker	[53]
SNAP23	OTY2MYBX	Strong	Biomarker	[54]
SOX10	OTF25ULQ	Strong	Biomarker	[55]
SS18L1	OT9ZEGV7	Strong	Genetic Variation	[56]
SS18L2	OTBSOW3J	Strong	Biomarker	[57]
SSX3	OTGJV5UZ	Strong	Biomarker	[58]
SYCP1	OTWFV4KA	Strong	Genetic Variation	[59]
TBC1D25	OT11OABF	Strong	Biomarker	[60]
TSPYL2	OTGGW2EF	Strong	Genetic Variation	[61]
RAD23B	OT0PGOG3	Definitive	Genetic Variation	[62]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of Adaptimmune.
• [3] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT01469975) First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (SYNFRIZZ). U.S. National Institutes of Health.
• [6] Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.Elife. 2018 Nov 15;7:e41305. doi: 10.7554/eLife.41305.
• [7] TLE1 Expression in Malignant Rhabdoid Tumor and Atypical Teratoid/Rhabdoid Tumor.Pediatr Dev Pathol. 2018 Nov-Dec;21(6):522-527. doi: 10.1177/1093526618761720. Epub 2018 Feb 28.
• [8] SRC signaling is crucial in the growth of synovial sarcoma cells.Cancer Res. 2013 Apr 15;73(8):2518-28. doi: 10.1158/0008-5472.CAN-12-3023. Epub 2013 Apr 11.
• [9] Longitudinal analysis of tear cathepsin S activity levels in male non-obese diabetic mice suggests its potential as an early stage biomarker of Sjgren's Syndrome.Biomarkers. 2019 Feb;24(1):91-102. doi: 10.1080/1354750X.2018.1514656. Epub 2018 Sep 12.
• [10] A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646.
• [11] Influence of alpha thalassaemia on the retinopathy of homozygous sickle cell disease.Br J Ophthalmol. 1993 Feb;77(2):89-90. doi: 10.1136/bjo.77.2.89.
• [12] Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.Hum Pathol. 2017 Mar;61:130-139. doi: 10.1016/j.humpath.2016.12.006. Epub 2016 Dec 16.
• [13] A synovial sarcoma with a complex t(X;18;5;4) and a break in the ornithine aminotransferase (OAT)L1 cluster on Xp11.2.Genes Chromosomes Cancer. 1994 Apr;9(4):288-91. doi: 10.1002/gcc.2870090409.
• [14] PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.Oncoimmunology. 2018 Sep 11;7(12):e1507600. doi: 10.1080/2162402X.2018.1507600. eCollection 2018.
• [15] SHCBP1 promotes synovial sarcoma cell metastasis via targeting TGF-1/Smad signaling pathway and is associated with poor prognosis.J Exp Clin Cancer Res. 2017 Oct 11;36(1):141. doi: 10.1186/s13046-017-0616-z.
• [16] ATR Is a Therapeutic Target in Synovial Sarcoma.Cancer Res. 2017 Dec 15;77(24):7014-7026. doi: 10.1158/0008-5472.CAN-17-2056. Epub 2017 Oct 16.
• [17] BCOR-CCNB3-positive soft tissue sarcoma with round-cell and spindle-cell histology: a series of four cases highlighting the pitfall of mimicking poorly differentiated synovial sarcoma.Histopathology. 2016 Nov;69(5):792-801. doi: 10.1111/his.13001. Epub 2016 Jul 15.
• [18] SMARCB1-deficient Tumors of Childhood: A Practical Guide.Pediatr Dev Pathol. 2018 Jan-Feb;21(1):6-28. doi: 10.1177/1093526617749671. Epub 2017 Dec 27.
• [19] Clinical application of RNA sequencing in sarcoma diagnosis: An institutional experience.Medicine (Baltimore). 2019 Jun;98(25):e16031. doi: 10.1097/MD.0000000000016031.
• [20] Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.Oncol Lett. 2019 Apr;17(4):3937-3943. doi: 10.3892/ol.2019.10044. Epub 2019 Feb 14.
• [21] CRABP1 provides high malignancy of transformed mesenchymal cells and contributes to the pathogenesis of mesenchymal and neuroendocrine tumors.Cell Cycle. 2014;13(10):1530-9. doi: 10.4161/cc.28475. Epub 2014 Mar 12.
• [22] Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.Oncotarget. 2018 Oct 12;9(80):35141-35161. doi: 10.18632/oncotarget.26216. eCollection 2018 Oct 12.
• [23] Antibodies to aquaporins are frequent in patients with primary Sjgren's syndrome.Rheumatology (Oxford). 2017 Dec 1;56(12):2114-2122. doi: 10.1093/rheumatology/kex328.
• [24] Activating transcription factor 2 in mesenchymal tumors.Hum Pathol. 2014 Feb;45(2):276-84. doi: 10.1016/j.humpath.2013.09.003. Epub 2013 Nov 27.
• [25] Epigenetic ConFUSION: SS18-SSX Fusion Rewires BAF Complex to Activate Bivalent Genes in Synovial Sarcoma.Cancer Cell. 2018 Jun 11;33(6):951-953. doi: 10.1016/j.ccell.2018.05.011.
• [26] New fusion sarcomas: histopathology and clinical significance of selected entities.Hum Pathol. 2019 Apr;86:57-65. doi: 10.1016/j.humpath.2018.12.006. Epub 2019 Jan 8.
• [27] HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma.PLoS One. 2017 Jan 5;12(1):e0169407. doi: 10.1371/journal.pone.0169407. eCollection 2017.
• [28] Expression of TLE-1 and CD99 in Carcinoma: Pitfalls in Diagnosis of Synovial Sarcoma.Appl Immunohistochem Mol Morphol. 2018 Jul;26(6):368-373. doi: 10.1097/PAI.0000000000000436.
• [29] Influence of TGF-1 expression in endothelial cells on smooth muscle cell phenotypes and MMP production under shear stress in a co-culture model.Cytotechnology. 2019 Apr;71(2):489-496. doi: 10.1007/s10616-018-0268-7. Epub 2019 Feb 1.
• [30] Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas and regulated by an Ets family transcription factor, ELF3.J Biol Chem. 2006 Dec 15;281(50):38941-50. doi: 10.1074/jbc.M608389200. Epub 2006 Oct 23.
• [31] Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas.Oncogene. 2004 Jul 15;23(32):5551-7. doi: 10.1038/sj.onc.1207710.
• [32] Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.Am J Surg Pathol. 2007 Jan;31(1):85-94. doi: 10.1097/01.pas.0000213413.33558.85.
• [33] Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.Mol Cancer Res. 2006 Jul;4(7):499-510. doi: 10.1158/1541-7786.MCR-05-0141.
• [34] KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model.Clin Exp Metastasis. 2010 Dec;27(8):591-600. doi: 10.1007/s10585-010-9349-5. Epub 2010 Sep 16.
• [35] Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma.Clin Transl Oncol. 2019 Dec;21(12):1624-1633. doi: 10.1007/s12094-019-02090-2. Epub 2019 Apr 8.
• [36] Sequence variations in the 5' flanking and IVS-II regions of the G gamma- and A gamma-globin genes of beta S chromosomes with five different haplotypes.Blood. 1991 Jun 1;77(11):2488-96.
• [37] Certain mutations observed in the 5' sequences of the G gamma- and A gamma-globin genes of beta S chromosomes are specific for chromosomes with major haplotypes.Acta Haematol. 1991;85(2):79-87. doi: 10.1159/000204862.
• [38] Glycogen synthase kinase 3 as a potential therapeutic target in synovial sarcoma and fibrosarcoma.Cancer Sci. 2020 Feb;111(2):429-440. doi: 10.1111/cas.14271. Epub 2019 Dec 30.
• [39] Inhibin- and synaptophysin immunoreactivity in synovial sarcoma with granular cell features.Hum Pathol. 2012 Jun;43(6):850-7. doi: 10.1016/j.humpath.2011.07.012. Epub 2011 Nov 4.
• [40] Refined mapping of the human Ets-related gene Elk-1 to Xp11.2-p11.4, distal to the OATL1 region.Hum Genet. 1994 Oct;94(4):442-4. doi: 10.1007/BF00201610.
• [41] The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.Cancer Cell. 2018 Mar 12;33(3):527-541.e8. doi: 10.1016/j.ccell.2018.01.018. Epub 2018 Mar 1.
• [42] Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines.Oncotarget. 2017 Aug 24;8(44):77254-77267. doi: 10.18632/oncotarget.20460. eCollection 2017 Sep 29.
• [43] Targeted disruption of the synovial sarcoma-associated SS18 gene causes early embryonic lethality and affects PPARBP expression.Hum Mol Genet. 2006 Oct 1;15(19):2936-44. doi: 10.1093/hmg/ddl235. Epub 2006 Aug 22.
• [44] The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma.Mol Cell Biol. 2007 Feb;27(4):1348-55. doi: 10.1128/MCB.00658-06. Epub 2006 Nov 13.
• [45] PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours.Histopathology. 2018 Oct;73(4):645-652. doi: 10.1111/his.13689. Epub 2018 Aug 2.
• [46] SYT-SSX1 (synovial sarcoma translocated) regulates PIASy ligase activity to cause overexpression of NCOA3 protein.J Biol Chem. 2011 May 27;286(21):18623-32. doi: 10.1074/jbc.M110.176693. Epub 2011 Mar 24.
• [47] A comparison of sickle cell syndromes in northern Greece.Br J Haematol. 1991 Mar;77(3):386-91. doi: 10.1111/j.1365-2141.1991.tb08589.x.
• [48] Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.BMC Cancer. 2018 Feb 7;18(1):158. doi: 10.1186/s12885-018-4066-6.
• [49] Amplification of the c-myc proto-oncogene in soft tissue sarcomas.Oncology. 1994 Jan-Feb;51(1):13-7. doi: 10.1159/000227302.
• [50] The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy.Clin Rheumatol. 2018 Jun;37(6):1573-1580. doi: 10.1007/s10067-018-4031-4. Epub 2018 Mar 15.
• [51] Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases.Tumour Biol. 2012 Dec;33(6):2245-53. doi: 10.1007/s13277-012-0486-0. Epub 2012 Sep 14.
• [52] The synovial sarcoma associated protein SYT interacts with the acute leukemia associated protein AF10.Oncogene. 2001 May 31;20(25):3281-9. doi: 10.1038/sj.onc.1204419.
• [53] Developmental SALL2 transcription factor: a new player in cancer.Carcinogenesis. 2017 Jul 1;38(7):680-690. doi: 10.1093/carcin/bgx036.
• [54] SNAP-23 and VAMP-3 contribute to the release of IL-6 and TNF from a human synovial sarcoma cell line.FEBS J. 2014 Feb;281(3):750-65. doi: 10.1111/febs.12620. Epub 2013 Dec 13.
• [55] The Roles of Sox Family Genes in Sarcoma.Curr Drug Targets. 2016;17(15):1761-1772. doi: 10.2174/1389450117666160502145311.
• [56] Novel SS18-NEDD4 gene fusion in a primary renal synovial sarcoma.Genes Chromosomes Cancer. 2020 Mar;59(3):203-208. doi: 10.1002/gcc.22814. Epub 2019 Oct 21.
• [57] Common origin of the human synovial sarcoma associated SS18 and SS18L1 gene loci.Cytogenet Genome Res. 2006;112(3-4):222-6. doi: 10.1159/000089874.
• [58] A novel Krppel-associated box containing the SSX gene (SSX3) on the human X chromosome is not implicated in t(X;18)-positive synovial sarcomas.Cytogenet Cell Genet. 1996;73(3):179-83. doi: 10.1159/000134334.
• [59] Reactivity of germ cell maturation stage-specific markers in spermatocytic seminoma: diagnostic and etiological implications.Lab Invest. 2001 Jul;81(7):919-28. doi: 10.1038/labinvest.3780302.
• [60] Identification of a yeast artificial chromosome (YAC) spanning the synovial sarcoma-specific t(X;18)(p11.2;q11.2) breakpoint.Genes Chromosomes Cancer. 1993 Mar;6(3):182-9. doi: 10.1002/gcc.2870060309.
• [61] Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.Oncoimmunology. 2018 May 31;7(8):e1467856. doi: 10.1080/2162402X.2018.1467856. eCollection 2018.
• [62] Contribution of STAT3 and RAD23B in Primary Szary Cells to Histone Deacetylase Inhibitor FK228 Resistance.J Invest Dermatol. 2019 Sep;139(9):1975-1984.e2. doi: 10.1016/j.jid.2019.03.1130. Epub 2019 Mar 22.